Short answer
CG Oncology, Inc. (CGON) filed its Q3 2025 10-Q quarterly report on Nov 14, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $2M (up 3774.4% year over year) with net income of −$44M.
Q3 2025 key financials · XBRL
- Revenue
- $2M
- +3774.4% YoY
- Net income
- −$44M
- −114.7% YoY · −5.8% QoQ
- Operating margin
- -3069.0%
- EPS (diluted)
- −$0.57
- −90.0% YoY · −3.6% QoQ
Source: XBRL data from the CG Oncology, Inc. (CGON) Q3 2025 10-Q on SEC EDGAR. USD.
CG Oncology, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- Newly added risk factor: potential delays in clinical trials triggered by supply chain disruptions in H1 2025
- Most materially updated risk: increased competition risk due to three new therapies entering market in Q2 2025
- Regulatory risk: ongoing FDA review delays extending from 12 to 18 months for key product approval timing
- Operational risk: manufacturing scale-up challenges causing projected capacity shortfall of 15% in Q3 2025
- Financial risk: liquidity constrained by $45M debt maturing in December 2025 with limited refinancing options
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other CG Oncology, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.